763E Concord Avenue
6 articles with Cyteir Therapeutics
Cyteir Therapeutics snagged $29 million and a new chief executive officer as the company pushes forward to develop small-molecule inhibitors in the fight against cancer.
Cyteir Therapeutics Secures $29 Million Series B to Advance Novel, Molecularly Targeted Therapies for Cancer and Autoimmune Diseases
Financing proceeds will be used to advance RAD51 inhibitor toward the clinic and expand small-molecule synthetic lethality platform for oncology and autoimmune diseases.
Cyteir Therapeutics Announces Study Showing RAD51 Modulators Protect Diabetic Mice From Type 1 Diabetes (T1D)
Cyteir Therapeutics Presents Preclinical Data Validating RAD51-AID As A Novel Target For Cancer Treatment At AACR Annual Meeting
Cyteir Therapeutics Presents Preclinical Data On Use Of DNA Repair Modulators For Lymphoid Malignancies At American Society of Hematology Annual Meeting